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Atypical mycobacteriaAbstract Non Tuberculous Mycobacteria (NTM) can cause severe infection in selected groups of
patients and is very difﬁcult to be differentiated from TB infection clinically or radiologically lead-
ing to miss diagnosis and wrong treatment in these cases, the Aim of the present study is to study risk
factors associated with NTM disease in patients with Acid Fast Bacilli (AFB) smear positive, Sub-
jects and methods: 1402 patients with AFB smear positive were included in the study, only 47
patients from the study group proved to have NTM disease (diagnosis was done according to
ATS/IDSA criteria). Results: the mean age of the NTM patients was 61.8 ± 23.2 years, NTM
was more common in older age groups and more common in white race patients, on using logistic
regression analysis NTM disease was more commonly associated with old TB infection (42.6%) and
with bed ridden patients on tracheostomy (31.9%). The most common organisms isolated were the
MAC complex (55.3%) followed by M. Kansasii (34.04%). Conclusion: NTM disease should be put
into consideration in patients with AFB smear positive and suffering from old TB infection or in
bed ridden patients who are on tracheostomy, also if smear is positive for AFB and PCR is negative
NTM should be suspected.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B.V. Open access under CC BY-NC-ND license.Introduction
Pulmonary tuberculosis (TB) remains an important public
health problem with an estimated 9.27 million new cases
worldwide in 2007 [1]. According to the current treatment
guidelines, isolation ofMycobacterium tuberculosis from a spu-
tum culture is still recommended to conﬁrm the diagnosis of
pulmonary TB [2]. Non-tuberculous mycobacteria (also called
atypical mycobacteria, mycobacteria other than tuberculosis,
environmental mycobacteria, opportunistic mycobacteria) are
ubiquitous pathogens and have been found in soil, domestic
tap water, and in animals [3,4]. Although exposure to non-
Table 1 Clinical and microbiologic criteria for diagnosing nontuberculous mycobacterial (NTM) lung disease.
Clinical (both required)
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph, or a high-resolution computed tomography scan that shows
multifocal bronchiectasis with multiple small nodules
2. Appropriate exclusion of other diagnoses
And
Microbiologic
1. Positive culture results from at least two separate expectorated sputum samples. If the results from [1] are nondiagnostic, consider repeat
sputum AFB smears and cultures
Or
2. Positive culture results from at least one bronchial wash or lavage
Or
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inﬂammation or AFB) and positive
culture for NTM or biopsy showing mycobacterial histopathologic features (granulomatous inﬂammation or AFB) and one or more
sputum or bronchial washings that are culture positive for NTM
4. Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that usually represent
environmental contamination
5. Patients who are suspected of having NTM lung disease but do not meet the diagnostic criteria should be followed until the diagnosis
is ﬁrmly established or excluded
6. Making the diagnosis of NTM lung disease does not, per se, necessitate the institution of therapy, which is a decision based on potential
risks and beneﬁts of therapy for individual patients
658 H. Shaarawy, A.T. Elhawarytuberculous mycobacteria often occurs without any clinical
manifestations, there are differences in the virulence of these
mycobacteria and clinical manifestations may range from no
symptoms or signs to destructive or even fatal disease [5].
Also with advances in the recognition of Nontuberculous
mycobacterium (NTM), prior studies have addressed the dif-
ﬁculty in distinguishing TB from NTM by using either clini-
cal symptoms or imaging [5,6]. The decision to initiate TB
treatment should be based on epidemiology, clinical/radio-
graphic ﬁndings, and the results of acid-fast bacilli (AFB)-
stained sputum. In endemic areas, it is not uncommon to
administer anti-TB treatment empirically pending culture re-
sults, given the clinical features suggesting pulmonary TB
[3,4]. Although this strategy aims at better disease transmis-
sion control, it comes with a price: it is possible to inappro-
priately treat patients without pulmonary TB with anti-TB
drugs, leading to adverse effects and unnecessary costs. In
addition the isolation prevalence of NTM has also increased
gradually, further complicating the problem [7]. Sputum AFB
staining is one of the most readily accessible tools for evalu-
ating patients suspected of having pulmonary TB; however, it
is not speciﬁc for pulmonary TB [4,8]. Pulmonary non-tuber-
culous mycobacteria (NTM) infection can cause severe
progressive illness which may be preceded by a period of
colonization [9,10]. Treatment of pulmonary NTM is
complicated, requiring multiple antimycobacterial drugs for
>12 months [9,10]. Patients are treated based on sputum
smear exams using standard ﬁrst and second line TB therapy
depending on clinical criteria in conjunction with the World
Health Organization (WHO) guidelines [11]. As NTM are of-
ten resistant to ﬁrst-line anti-TB medication, presumably
many of these cases would be considered treatment failures,
and subsequently treated for multi-drug resistant (MDR)
disease [12]. Colonization, on the other hand, may be deﬁned
by the absence of one or more diagnostic criteria [12]. In the
setting of colonization, treatment is often withheld owing to
its potential toxicities and the uncertain rate of progression.
Ideally, treatment should be initiated before irreversible lung
damage occurs or progresses [13].Aim of the work
The aim of the present study is to study the risk factors asso-
ciated with Non-Tuberculous (NTM) mycobacterial disease in
patients with smear positive pulmonary TB.Subjects
The study was done in the pulmonary rehabilitation center,
ministry of health, state of Kuwait. Pulmonary rehabilitation
center is the main center in the state of Kuwait that is speciﬁed
to diagnose and treat Tuberculosis and all cases of TB whether
pulmonary or extra-pulmonary are referred to the center for
evaluation and putting the plane of treatment, also pulmonary
rehabilitation center is the supervisor of the central TB labora-
tories speciﬁed for microbiological diagnosis of TB. 1402
patients with AFB smear positive sputum or BAL admitted
to the center were included in the present study, cases were
admitted for isolation and more assessment to conﬁrm the
diagnosis of pulmonary TB and to start speciﬁc treatment,
the study was done in the period from 1/1/2010 to 30/6/2013,
from these patients 47 patients were conﬁrmed to have NTM
disease (according to ATS criteria Table1).Methods
All patients were subjected to the following:
1- History taking.
2- Physical examination.
3- Three successive samples of Sputum for AFB were col-
lected in the early morning for 3 successive days. If the
patient was not able to give sputum spontaneously
induction of sputum using a hypertonic saline nebulizer
in the early morning preceded by salbutamol inhalation
or bronchoscopy and broncho-alveolar lavage was used
to get the sample for bacteriological analysis, all sputum
Table 2 Epidemiologic criteria and co-morbidities associated
with NTM Disease.
Age in years 61.8 ± 23.2
Age range 36–83
Male:female 29 (61.7%)–18 (38.3%)
Ethinisty White:non white = 30/17
Co-morbidities associated with NTM disease
Old TB history 20 (42.6%)




Table 3 Clinical characteristics of NTM patients.
Chronic cough 32 (68%)
Sputum production 30 (63.8%)
Fever 22 (46.8%)
Hemoptysis 5 (10.6%)
Chest pain 7 (14.9%)
Table 4 Radiographic characters (by CXR and CT chest) of
the NTM patients.
Unilateral vs Bilateral 19 (40.4%):28 (59.6%)
Consolidation 17 (36.2%)
Cavitation 7 (14.9%)
Nodular, reticulonodular 36 (76.6%)
Honeycombing 4 (8.5%)
Pleural eﬀusion 2 (4.3%)
Risk factors for mycobacterial disease in patients with smear positive pulmonary TB 659or BAL samples were sent for direct smear examination
using Ziehl–Neelsen stain and culture for mycobacterial
tuberculosis obtained using solid and liquid media and
samples were incubated for 8 weeks before the ﬁnal
results were declared.
4- In bed-ridden cases on tracheostomy tracheal aspirate
were sent for culture and sensitivity for acid-fast bacilli.
5- TB polymerase chain reaction (PCR) performed with in-
house IS6110-based PCR assays [14] was done in spu-
tum or BAL samples positive for AFB and suspected
to be atypical mycobacteria.
6- Chest X ray.
7- Computed tomography (CT chest) with contrast was
done in all suspected cases of being atypical mycobacte-
ria infection.
8- In cases identiﬁed to be Non-Tuberculous Mycobacteria
(NTM) isolates were identiﬁed by DNA probes (AccuP-
robe; Gen-Probe Incorporated and GenoType line-
probe assays; Hain Life Science.
9- NTM disease was diagnosed according to ATS/IDSA
criteria (Table 1) [15].
Statistical analysis
All statistical analyses were conducted using the software
package SPSS 20.0 for Windows (SPSS Inc., Chicago, IL,
USA). Data are presented as frequencies for categorical
variables, and by mean ± standard deviation for numerical
variables. Categorical variables were compared using a chi-
square test, and continuous variables were compared using
an independent unpaired t-test. Multivariate analysis was
conducted using a logistic regression model to determine the
independent predictive factors for atypical mycobacteria dis-
ease among cases of smear positive pulmonary TB. p-values
less than 0.05 were considered signiﬁcant.
Results
From 1-1-2010 to 30-6-2013 out of the 1402 patients with spu-
tum or BAL smear positive for AFB; 47 patients were con-
ﬁrmed to have NTM disease (according to ATS criteria
Table 1).
From Table 2: NTM disease was found mainly in older age
groups (mean age was 61.8 years) although there was a wide
range for the age distribution, NTM was more common in
males than in females and was more common in the white race.
The most common co-morbidity associated with NTM disease
was old TB infection which was present in 20 patients (42.6%)
followed by bed ridden patients who were on tracheostomy
which was found in 15 patients (31.9%), this was followed
by COPD which was found in 7 patients (14.9%). Table 3
demonstrates the clinical characters of the NTM patients.
From Table 4: the most common radiographic feature
detected in these patients was the nodular or reticulonodular
inﬁltrate which was present in 36 patients (76.6%) followed
by consolidation which was present in 17 patients (36.2%),
disease was bilateral in 19 patients (40.4%) and was unilateral
in 28 patients (59.6%).
From Table 5: 141 samples were studied (through sputum,
BAL or tracheal aspirate), from these samples 120 (85.1%)samples were positive for AFB and 126 (89.4%) samples
showed positive culture for NTM with a minimum of 2 cul-
tures for each patient , PCR test for mycobacteria TB was neg-
ative in all samples whether positive or negative for AFB. On
using Gene probe identiﬁcation of the NTM species the most
isolated organism was MAC complex (mycobacteria avium–
intercellulare complex) which was present in 26 patients
(55.3%) followed by mycobacteria Kansasii which was present
in 16 patients (34.04%), Mycobacteria Abscessus was present
in 4 patients (8.53%) and Mycobacteria gordoni was present
in 1 (2.13%) patient. On using multivariate logistic regression
analysis to identify risks associated with NTM disease among
AFB smear positive cases the only 2 variables that showed sig-
niﬁcant correlation were old TB infection and bed ridden pa-
tients on tracheostomy (p< 0.05).
Discussion
The aim of the present study was to study the possible risk
factors associated with non tuberculous mycobacterial disease
in smear positive pulmonary TB patients, at the center in
which the study was done is the main center in the state of
Kuwait dealing with Tuberculosis; from every patient admitted
to the center 3 samples of sputum, induced sputum, tracheal
aspirate or BAL were sent for AFB direct examination and
at the same time for AFB culture and sensitivity to be sure
Table 5 Microbiology characters of NTM patients.
No. of NTM patients 47
No. of AFB smear positive samples 120 (85.1%) of 141 samples
PCR for mycobacteria TB ve in all positive and negative samples (100%)
Culture +ve for NTM 126 (89.4%)





660 H. Shaarawy, A.T. Elhawaryof the diagnosis and to detect drug sensitivity, as NTM disease
is very difﬁcult to be differentiated from pulmonary TB on
clinical or radiological features mycobacterial culture results
can be the corner stone to solve the problem and avoid the
un-necessary isolation of these patients and in the same time
it helps in prescribing the correct drug regime for these patients
[15]. In the present study the main risk factor associated with
atypical mycobacterial disease was the presence of old TB
infection (42.6% of NTM cases had old TB), old TB causes
parenchymal destruction in the lung with ﬁbrosis or cavitary
changes leading to reduction in the physiologic protective
mechanisms of the lung against invasion by bacteria, and as
NTM are non-virulent organisms the diseased lung constitutes
good media for invasion by these organisms, on the other hand
the patients with old TB infection may be at increased risk for
poor nutrition, poor hygienic measures in the surrounding
environment leading to increased risk for NTM disease [16–
19]. Da costa et al. in 2013 studied the occurrence of NTM
infection in an endemic area of tuberculosis, the NTM infec-
tion constituted 13.5% of positive mycobacterial cultures over
2-years period, a major risk factor for NTM pulmonary dis-
ease was previous tuberculosis (76%) [20]. The second risk fac-
tor associated with NTM in the present study was bed ridden
patients who are on tracheostomy for long periods (31.9% of
cases), these patients have deﬁciency in the natural protective
mechanisms of the upper airways and they are in continuous
contact with the external environment together with the
impaired cough reﬂex in most of these patients leading to eas-
ily invasion of the lungs by opportunistic organisms like NTM,
adding to this is the nutritional deﬁciency and other co-
morbidities associated with bed ridden condition leading to de-
crease in the immune status of these patients. In a study done
by Derac et al. in 2012 they used a comparative, population-
based design to examine aerosol-generating behaviors in the
home and garden and several pulmonary and non-pulmonary
conditions as potential risk factors for Mycobacterium avium
complex lung disease in an HIV-negative, general adult popu-
lation and they concluded that aerosol-generating activities
seem not to be risk factors for Mycobacterium avium complex
lung disease in HIV-negative adults, but prior lung disease and
immune-suppressing drugs seem to be associated with suscep-
tibility [21]. On raising the concept of colonization of NTM in
these patients all patients included in the present study had at
least 2 positive cultures of NTM associated with newly
developed clinical manifestations or radiologic manifestations,
the concept of airway colonization by NTM has never been
tested rigorously. There is not enough known about the
pathophysiology of NTM lung disease to be sure that
colonization is not, in fact, an indolent or slowly progressiveinfection. No pathologic studies have been done to demon-
strate the absence of tissue invasion, and more recent studies
with HRCT have shown that these patients often have a com-
bination of multifocal bronchiectasis and nodular parenchy-
mal disease now believed to be due to mycobacterial disease
[15,22,23]. As regards the gene probe identiﬁcation the most
common organism encountered in the present study was
Mycobacterium avium complex (MAC) which was found in
55.3% of the cases followed by M. Kansasii which was found
in 34.04% of the cases, the NTM distribution is different from
one region of the world to the other, lack of large studies and
reporting data adds to difﬁculty in interpreting data. In the last
2 reports published in the USA about the prevalence of Non-
Tuberculous Mycobacteria MAC was the most common to be
isolated followed by M. fortuitum then M. Kansasii [24,25]
while in the study done by Derac et al. in 2012 which was done
in Brazil the distribution was different as the rapidly growing
Mycobacterium massiliense and Mycobacterium simiae com-
plex were most dominant [21].
Conclusion
NTM disease should be put into consideration in patients with
AFB smear positive and suffering from old TB infection or in
bed ridden patients who are on tracheostomy, also if smear is
positive for AFB and PCR is negative NTM should be
suspected.Conﬂict of interest
We have no conﬂict of interest to declare.
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